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Tissue equivalencyHumans make high levels of antibody to carbohydrates with terminal galactose a 1,3 galactose (Gal)
modifications. This Gal antigen is widely expressed in other mammals and is present on an array of cur-
rent animal derived biomedical devices including bioprosthetic heart valves. There is growing interest in
using Gal-free animal tissues from Gal knockout pigs (GTKO) as these tissues would not be affected by
anti-Gal antibody mediated injury. In this study we compare the composition and biophysical character-
istics of glutaraldehyde fixed porcine pericardium from standard and GTKO pigs. We show that with the
exception of the Gal antigen which is only present in standard pig tissue both GTKO and standard pig tis-
sue have the same general morphology and collagen content. Moreover uniaxial stress testing and suture
retention testing indicate the tissues are equivalent in tensile strength. These studies indicate that
genetic disruption of the a-galactosyltransferase (GGTA-1) which blocks synthesis of the Gal antigen
has no significant impact on the structural integrity of porcine pericardium and suggest that this tissue
could be directly substituted for standard pig pericardium in biomedical devices such as bioprosthetic
heart valves.
Statement of Significance
Surgical heart valve replacement is a proven life saving therapy to treat heart valve dysfunction due to
birth defects, infection and the effects of aging. Bioprosthetic heart valves (BHV) made from glutaralde-
hyde fixed animal tissues are an effective durable therapy in older patients (>60 years) but exhibit age-
dependent structural valve degeneration (SVD) in younger patients (<60 years). SVD is principally caused
by BHV calcification. Immune injury contributes to age-dependent SVD through the interaction of galac-
tose a 1,3 galactose (Gal) a dominant xenogeneic antigen present on commercial BHVs and universally
abundant human anti-Gal antibody. This study measures the tissue equivalency between standard pig
pericardium and Gal-free pericardium from genetically modified pigs as a first step towards making
Gal-free BHVs.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Bioprosthetic heart valves (BHVs) have been produced from
bovine and porcine tissues for over 50 years. These devices have
been very successful as valve replacement therapy to treat heartvalve disease and recent trends show a significant shift towards
their use compared to mechanical heart valves (MHVs) [1]. BHVs
have better hemodynamic properties compared to MHVs and gen-
erally do not require chronic anticoagulant therapy which is neces-
sary for MHVs [2]. Nevertheless, despite more than half a century
of extensive scientific and clinical investigations, current BHVs
remain associated with limited durability due to structural valve
degeneration (SVD) caused by dystrophic calcification, inflamma-
tion, and leaflet tearing resulting in failure of the prosthesis. The
frequency of SVD is not constant but is strongly affected by patient
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(>75 years) have freedom from SVD. This falls to 55% in patients
aged 60–75 years. Up to 100% of BHVs fail within 5 years in
patients <35 years of age [4].
Clinical BHVs are based on glutaraldehyde fixation of bovine or
porcine pericardium or the use of porcine heart valves. This basic
technology has been augmented with various post fixation anti-
calcification processing strategies to reduce dystrophic BHV calci-
fication [5,6]. These anti-calcification processes are commonly
designed to extract phospholipids which are thought to act as a
nidus for calcium binding. Testing in juvenile animal models shows
significant reduction of BHV calcification after anti-calcification
treatments [5–10] but there is scant evidence for a clinical
improvement in BHV durability or prevention of age-dependent
SVD. This suggest that calcification in juvenile animal models pri-
marily results from passive, phospholipid-dependent, calcification
but that in patients additional mechanism(s) contribute to calcific
BHV degeneration, particularly to age dependent SVD.
SVD has long been associated with an inflammatory response
[2]. Recent studies of BHVs derived from left ventricular assist
devices show early fibrin deposition, microthrombi formation,
and macrophage, antibody, and complement infiltration into the
BHV matrix after limited implantation in patients and prior to evi-
dence of calcification, infection or pannus growth [2,11–13]. This
pathology is consistent with an antibody mediated BHV immune
injury which can promote tissue calcification [14]. We have
recently demonstrated that antibody universally present in high
quantities in humans to the xenogeneic carbohydrate galactose a
1,3 galactose (Gal) accelerates calcification of glutaraldehyde fixed
porcine pericardium but does not increase calcification of Gal-free
pericardium derived from pigs with a mutation in the GGTA-1 gly-
cosyltransferase (GTKO pigs) required for synthesis of the Gal anti-
gen [15]. This anti-Gal antibody induced calcification occurs even
after the tissues are treated with phospholipid extracting anti-
calcification processing confirming that immune injury can inde-
pendently affect tissue calcification [16].
The Gal antigen is widely expressed in porcine and bovine tis-
sue and is retained in currently used commercial BHVs [15,17].
Unlike protein antigens Gal remains immunogenic after fixation
and is reported to induce a transient induction of anti-Gal antibody
in adult patients [17,18] and a stronger sustained induction of anti-
Gal antibody in children [19] after BHV replacement surgery. In
non-human primates, the only other class of mammals which pro-
duce anti-Gal antibody, mitral valve replacement using commer-
cially prepared wild type and GTKO porcine BHVs resulted in
persistent and significantly elevated anti-Gal IgG level in WT
BHV recipients but not in GTKO BHV recipients [20]. The combina-
tion of anti-Gal antibody in patients, and the high level of Gal anti-
gen on commercial BHVs enables an immediate and chronic innate
antibody dependent inflammation of the valve without the need
for a specific immune induction which likely contributes to age-
dependent SVD. These results suggest that BHVs produced from
GTKO pig tissues and lacking the Gal antigen would be resistant
to anti-Gal induced calcification and may help to prevent age-
dependent SVD. This study tests the physical equivalence of wild
type and GTKO porcine pericardium as an essential first step
towards developing Gal-free GTKO BHVs.2. Materials and methods
2.1. Pig tissue processing and fixation
Genetically modified GGTA-1 deficient (GTKO) pigs were pro-
duced in accordance with the Animals (Scientific Procedures) Act
of 1986, published by the United Kingdom Home Office, and theGuide for the Care and Use of Laboratory Animals from the U.S.
National Institute of Health (Publication No. 85-23, revised 1996)
Conventional wild type (WT) pig tissues were obtained from a local
abattoir. Heart lung blocks were collected from GTKO or wild type
animals and chilled on ice prior to isolating the pericardium. Tis-
sues were rinsed with water and dissected to recover the pericar-
dial sac. The pericardial sac was rinsed in sterile saline (4 C) split
and cleaned of fat, rinsed extensively in sterile saline and stored
overnight at 4 C. Fresh pericardial samples were blotted dry and
frozen at 80 C. For fixation all tissues were fixed in 0.6% glu-
taraldehyde in 20 mM HEPES-Saline (pH 7.4) containing 13 mM
MgCl2-H2O for 24 h at 4 C, rinsed in sterile saline and stored in
the same buffer containing 0.2% glutaraldehyde at 4 C until used.2.2. Hydroxyproline
The hydroxyproline content of fixed WT and GTKO pericardium
was measured using dimethylamino-benzaldehyde (DMAB) after
oxidation with Chloramine T. Pericardium (1 mg wet weight) was
hydrolysed in 200 ll 6 N HCl at 120 C for 3 h. Hydrolysed samples
(10–50 ll) were transferred to 96-well plates and dried at 60 C
then incubated with 100 ll of Chloramine T for 5 min at room tem-
perature followed by a 90 min incubation at 60 C with 100 ll of
DMAB reagent as described by the manufacturer (Sigma Aldrich,
St Louis, MO, USA). The absorbance at 560 nm was measured using
a Genios plate reader (Tecan UK Ltd, Reading, UK). Hydroxyproline
content of pericardium was determined by reference to a standard
curve.2.3. Protein extraction, Gel electrophoresis and lectin blotting
Detergent soluble proteins were extracted from fresh split pig
pericardium by incubating the tissue (200 mg/ml) in 2 Laemmli
buffer (60 mM Tris pH 6.8, 2% SDS, 72 mM BME) at 4 C for 24 h.
Samples were centrifuged at 20,000g for 30 min at 4 C and
stored at 4 C. Collagen was isolated after acetic acid and pepsin
digestion and differential NaCl precipitation was used to character-
ize the collagen content essentially as described [21]. In brief, fresh
frozen pericardium was pulverized in liquid nitrogen, suspended
(5 mg/ml) in 2 M NaCl, 50 mM Tris, 1 mM EDTA (pH 7.4) contain-
ing freshly added 1 mM phenylmethanesulfonylfluoride (PMSF)
and N-ethylmaleimide (NEM) and incubated at 4 C for 24 h with
constant agitation. Samples were centrifuged at 30,000g for
40 min at 4 C and the pellet was incubated at 4 C overnight in
0.5 M acetic acid (pH 2.5). The sample was centrifuged and the pel-
let resuspended in fresh acetic acid containing pepsin (Sigma
Aldrich, St Louis, MO, USA) at a 1:10 pepsin:tissue ratio and incu-
bated at 4 C for 48 h. High molecular weight protein aggregates
were removed from the pepsin extract by precipitation with
0.6 M NaCl 4 C for 2 h and centrifugation. Crude collagen was
recovered by precipitation with 2 M NaCl at 4 C for 12 h. This pel-
let was dissolved in 50 mM Tris pH 7.4 and re-precipitated with
4 M NaCl to make a final total collagen extract. For differential col-
lagen precipitation the crude collagen pellet was dissolved in 0.5 M
acetic acid and dialysed against 0.4 M NaCl, 100 mM Tris (pH 7.4).
Differential collagen precipitation was achieved by sequential dia-
lysing against 1.7, 2.5 and 4.0 M NaCl, 100 mM Tris (pH 7.4). At
each NaCl concentration the samples were centrifuged and the
recovered pellets were dissolved in 50 mM Tris, 50 mM NaCl (pH
8) for analysis.
Progressive collagen precipitates were analysed by gel elec-
trophoresis using a 7.5% Mini-PROTEAN acrylamide gels under
non-reducing conditions (BioRad, Hercules, CA, USA). Separated
proteins were detected by silver staining (Invitrogen, Carlsbad,
CA, USA).
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on a 7.5% apparatus (7.5%Mini-PROTEAN TGXTM Gel, BioRad) under
reducing conditions and transferred to a PVDF membrane using a
BioRad Mini-Trans Blot Module for 2 h at 90 V. Membranes were
blocked with Dulbecco’s PBS containing 2% BSA and 0.3% Tween-
20 for 2 h at ambient temperature. Gal antigen was detected using
3 lg/ml biotin-conjugated Griffonia simplicifolia isolectin B4 (GSIB-
4, Vector Laboratories, Burlingame CA) diluted in blocking buffer
at 4 Covernight as recommendedby themanufacturer.Membranes
were washed in PBS containing 0.3% Tween-20 and GSIB-4 binding
was detected by incubating with 1 lg/ml horseradish peroxidase
(HRP) conjugated streptavidin (Pierce Streptavidin Poly-HRP,
ThermoScientific) for 2 hat roomtemperature. Streptavidinbinding
was observed with chemiluminescence (PierceTM ECL Western Blot-
ting Substrate, Thermo Scientific, Rockford, IL, USA) and recorded
with a myECL Imager (Fisher Scientific UK Ltd, Loughborough, UK).
2.4. Histology
Fresh and glutaraldehyde fixed pericardial sampleswere embed-
ded in Optimal Cutting Temperature material and cryosectioned
(8 lm). Sections were air dried, fixed with acetone for 10 min and
stored at80 C until used. Fresh and glutaraldehyde fixed samples
were also fixed in formalin and paraffin embed for Masson’s Tri-
chrome histology staining. Tissue sections were stained to detect
the Gal antigen and collagens. Fresh and glutaraldehyde fixed tis-
sues were stained with biotin-conjugated GSIB-4 (3 lg/ml) and
murine monoclonal antibodies (2 lg/ml) to Collagen I (Anti-
Collagen Type I, Sigma-Aldrich), III (Anti-Collagen Type III, Abcam,
Cambridge, UK), and V (Anti-Collagen Type V, Abcam). Lectin and
antibody solutionswere produced in dPBSwith 1% BSA and primary
incubations were at 4 C for 12 h. GSIB-4 binding was detected with
HRP-conjugated streptavidin (Sigma-Aldrich) and mouse anti-
collagen antibody bindingwas detectedwith biotin conjugated goat
anti-mouse IgG (Sigma-Aldrich) and HRP-conjugated streptavidin.
All sections were incubated with 3,30-Diaminobenzidine (Sigma-
Aldrich) and counter stained with haematoxylin.
2.5. Uniaxial tensile mechanical test
Dumbbell-shape test pericardial specimens were cut to 12 mm
gauge length and 2 mm width, according to type 4 test specimen
dimensions recommended by ISO 37-2011 [22]. Care was taken to
cut the specimen in such away to align the direction of the extracel-
lularmatrix (ECM)fibers at a45 angle relative to the axis of the sam-
ple. The thickness of each specimen was measured from three
equally spaced locationsalong the specimen lengthusingaMitutoyo
gauge (Mitutoyo Corporation, Tokyo, Japan) immediately prior to
testing. Uniaxial tensile test was performed for 32 samples of each
tissue group using a Zwickyline tensile test machine (Zwick.Roell
GmbH&Co,Ulm,Germany)equippedwitha2.5 kN loadcell, amedia
container with temperature control unit and test Xpert software.
Sampleswere submerged in 37 C saline and loaded to failure apply-
ing a cross-head displacement rate of 20 mm/min. The maximum
tensile force and strength, as well as the elongation at maximum
forcewereobtained.Tensile strength (ru, expressed inmegapascals)
was calculated by normalising the maximum tensile force (F,
expressed in Newtons) by unit area of the unloaded cross-section
of the specimen. Elongation at maximum force was determined as
the percentage of increase in length at the maximum force F, with
respect to the original length of the gauge.
2.6. Suture retention test
Suture retention tests were performed by pulling a suture from
the pericardial tissue sample to determine the force necessary totear the tissue. The test protocol was adopted from ANSI/AAMI/
ISO7198 [23]. WT (n = 15) and GTKO (n = 15) tissues were cut in
1  2 cm specimens and a multi-filament suture (Ethicon VICRYL
5-0) was inserted 2 mm from the edge of the sample. Tests were
performed on the Zwickyline tensile test machine, pulling the
suture at a speed of 50 mm/min. The maximum of the force
required to pull the suture through the sample was recorded.
2.7. Statistical analysis
All stress measurements were analysed using Microsoft Excel or
GraphPad Prism software (GraphPad, San Diego, CA) and presented
as means ± standard deviation. Where required, an unpaired two-
tailed t-test withWelch’s correction was used to compare two pop-
ulation means, and a P-value of <0.05 was considered significant.3. Results
3.1. Composition of Porcine WT and GTKO Pericardium
Split porcine pericardium is largely a matrix of extracellular
protein with strong trichrome collagen staining present in both
wild type (WT) and GTKO pericardium (Fig. 1). GSIB-4 lectin stain-
ing of fresh and glutaraldehyde fixed WT porcine pericardium
detects abundant Gal antigen expression (Fig. 1B and C). Soluble
competition using 10 mM Gal-trisaccharide eliminates the bulk
of GSIB-4 staining to WT tissue (insert Fig. 1B) and demonstrates
the specificity of lectin staining. There is no Gal expression evident
in fresh or fixed GTKO porcine pericardium (Fig. 1B and C).
Detergent soluble proteins and total collagen extracts from WT
and GTKO show similar protein profiles (Fig. 2A). GSIB-4 lectin
blotting of these extracts detects Gal antigen in WT detergent sol-
uble pericardial proteins but not in WT collagen or in GTKO deter-
gent soluble proteins or collagen extracts (Fig. 2B). Fixation of WT
pericardium prior to Laemmli buffer extraction appears to trap sol-
uble proteins and retains the Gal antigen (Fig. 2C) whereas
Laemmli extraction of fresh pericardium, consistent with the bio-
chemical analysis, is largely depleted of the Gal antigen (Fig. 2D).
Differential salt precipitation was used to compare the collagen
composition of WT and GTKO pericardium (Fig. 2E). Precipitation
with 1.7 M NaCl at neutral pH recovers mainly collagen III while
collagen I and V are precipitated in 2.5 and 4.0 M NaCl respectively
[21]. Both the WT and GTKO pericardium show typical [24] and
similar collagen profiles at each salt concentration (Fig. 2E). There
was no significant difference between WT and GTKO pericardium
in the hydroxyproline estimate of total collagen content (Fig. 2F).
Immunohistology of fresh WT and GTKO pericardium detects col-
lagen I, III, and V staining in both tissues (Fig. 3) and is consistent
with the differential salt precipitation of collagen in Fig. 2E.
3.2. Stress testing of fixed WT and GTKO pericardium
Uniaxial stress testing was used to compare the physical proper-
ties of fixedWTandGTKOpericardium. For these tests sample thick-
ness was measured as 149.4 ± 32.2 lm and 158.1 ± 32.8 lm
(mean ± standard deviation) for WT and GTKO pericardium which
was not significantly different. Tensile strength recorded as
16.2 ± 7.5 MPa and 17.6 ± 7.5 MPa for WT and GTKO pericardium,
respectively (Fig. 4A–C) andwas not significantly different between
the two tissues. The Young’s modulus was calculated at regions of
low and high stiffness in the stress strain profile for each tissue type.
In the low stiffness region, correspondingmore closely to the forces
exerted on valves in a BHV, Young’s modulus was 42.8 kPa and
48.6 kPa forWT andGTKO respectively (P value = 0.654). In the high
stiffness region, young’s modulus was 386.8 kPa and 593.3 kPa for
AB
C
WT fresh GTKO fresh
WT fixed GTKO fixed
WT GTKO
Fig. 1. Morphology of WT and GTKO pig pericardium. A. Trichrome stain. B and C. Immunohistochemistry using the lectin GSIB-4 to detect the Gal antigen in fresh (B) and
0.6% glutaraldehyde fixed (C) pericardium. Inserts in B show Gal-specific inhibition of lectin binding by 10 mM Gal trisaccharide. Scale bars are 20 lm in A, and 50 lm in B
and C.
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no significant difference but therewas a trend for the GTKO tissue to
be more resilient.
The forces measured in the suture retention tests to break the
WT and GTKO pericardium specimen by pulling the VICRYL 5-0
were not significantly different, measuring as 3.4 ± 0.9 and
3.8 ± 1.5 for the WT and GTKO respectively (Fig. 4D).4. Discussion
This study was designed to compare the composition and phys-
ical characteristics of WT and GTKO fixed porcine pericardium to
test for physical equivalence. The mutation of the GGTA-1 gene
in GTKO pigs only affects the terminal addition of alpha 1,3 linked
galactose to lactosamine. This change would not be expected to
substantially affect the physical properties of the tissue and we
find no evidence that WT and GTKO pericardium exhibit a compo-
sitional change, other than the absence of the Gal antigen in GTKO
pericardium, or any differences in the tensile stress properties of
the fixed tissue. Similarly bovine pericardium and porcine swine
intestine submucosa treated with alpha-galactosidase or in some
instances decellularized by detergent extraction have also been
reported to show elimination of the Gal antigen and physical
equivalence to untreated tissue [25–27] further supporting our
finding that the genetic elimination of Gal does not significantly
alter pericardial tissue integrity.
There is growing interest in using Gal-free tissues to develop
BHVs and other biomedical materials based on our research
[15,16,20,28] and others [17,19,29–31] indicating that the Galantigen is present on current clinical BHVs and surgical meshes
[31,32], remains immunogenic and that binding of human anti-
Gal antibody initiates a process leading to fixed tissue calcification
which may promote SVD. This immune mechanism may especially
contribute to age-dependent SVD where current anti-calcification
processing has not been effective. There are a range of clinical
reports where the combination of anti-Gal antibody and Gal anti-
gen may have contributed to BHV loss including catastrophic valve
failure in paediatric patients [33], BHV loss due to pork allergy [34],
immune rejection [35] and even hyperacute rejection of a pericar-
dial BHV [36]. Carbohydrate specific antibody mediated immune
injury may also affect ABO mismatched homografts as there is a
report of higher early reoperative rate in children with ABO incom-
patible cryopreserved homografts [37]. These experimental and
clinical results highlight the significance of carbohydrate antigens
which contrary to protein antigens are not effectively blocked by
fixation and support the case that BHVs made from pig tissues
devoid of the dominant xenogeneic glycan, Gal, are less immuno-
genic [20] and may result in more durable valves which resist
anti-Gal antibody mediated calcification.
Pig pericardium is mainly composed of collagen and a range of
associated proteins. The collagen component contains little of the
Gal antigen which is mainly present in detergent soluble matrix
associated glycoproteins (Fig. 1A and B). These Gal modified glyco-
proteins may be removed by detergent extraction from fresh peri-
cardium, but resist extraction after glutaraldehyde fixation
(Fig. 2C and D). The post-fixation retention of these proteins may
account for the continued presence of the Gal antigen in current
clinical BHVs which use detergent or ethanol based post-fixation
anti-calcification processing.
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polyacrylamide electrophoresis of detergent soluble (lanes 1 and 3) and total
pepsin treated collagen extracts (lanes 2 and 4) from WT and GTKO pig
pericardium. Both tissue sources show very similar profiles of extracted proteins.
B. Western blot of the gel in A using the Gal-specific lectin GSIB-4. Gal bearing
glycoproteins are evident only in proteins from the WT detergent extract. C. Fixed
WT pericardium extracted with Laemmli buffer and stained with GSIB-4. Fixation
traps detergent soluble proteins and retains Gal expression. D. Fresh WT
pericardium extracted with Laemmli buffer and stained with GSIB-4. Gal is largely
depleted by Laemmli extraction from fresh pericardium as indicated by the lectin
blot in B. E. Differential collagen precipitation from acetic acid pepsin digests of WT
(lanes 1, 3 and 5) and GTKO (lanes 2, 4 and 6) pericardium. The silver stained
polyacrylamide gel shows pepsin treated collagen extracts solubilised at 1.7, 2.5
and 4 M NaCl concentrations. Both tissue show the same collagen composition. F.
Hydroxyproline content of WT (n = 16) and GTKO (n = 16) pericardial samples.
Hydroxyproline is a common modified amino acid present in collagen and a useful
estimate of collagen content. Error bars are standard error of the mean. There is no
difference (Student’s t-test p > 0.05) between the samples. Scale bars in C and D are
50 lm.
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Fig. 4. Box and Whisker presentation of uniaxial stress testing of glutaraldehyde
fixed WT and GTKO pig pericardium (n = 32). A. Average maximum force (N)
applied until failure (4.7 ± 1.8 N and 5.4 ± 2.2 N for WT and GTKO respectively). B.
Average maximum stress (16.2 ± 7.5 MPa and 17.6 ± 7.5 MPa, for WT and GTKO
respectively). C. Average strain at maximum stress (66.6 ± 18.4% and 66.3 ± 16.2%,
for WT and GTKO respectively). D. Suture retention testing showing the maximum
force required to tear a suture through the tissue (3.4 ± 0.9 N and 3.8 ± 1.5 N for WT
and GTKO respectively, n = 15). No significance difference was detected between
the tissues using a 2-way Student’s t-test. Average values are ± the standard
deviation.
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Fig. 3. Immunohistology of collagen expression in WT and GTKO pig pericardium.
Fresh pericardium was stained with antibody to collagen I, III and V. Scale bars are
50 lm.
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mals of approximately 6 months of age and had an average thick-
ness of approximately 150 lm (Mean ± SEM, WT: 149.4 ± 5.7 lm
and GTKO: 158.1 ± 5.8 lm). This is thinner than typical bovine
pericardium and porcine heart valve leaflets. Thin tissue may be
beneficial for use in percutaneous designs and may have beneficial
effects on leaflet hydrodynamics but, may also have a negative
impact on valve durability. Test valves based on these tissues will
need to be developed to measure these parameters and to find an
optimum for tissue thickness and durability.
Gal is not the only xenogeneic carbohydrate antigen present on
commercial BHVs [38–40], but its high level of expression and the
abundance of anti-Gal antibody in patients suggests it will have a
disproportionate impact through this mechanism. Additional
genetic modification which further reduces the antigenicity of
pig tissue have been reported [40] suggesting that genetically
modified antigen reduced porcine tissues can be a platform tech-
nology for glutaraldehyde fixed BHVs in the short term and in
C. McGregor et al. / Acta Biomaterialia 41 (2016) 204–209 209the long term for regenerative strategies to develop living tissue
engineered heart valves and other devices.
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